A Phase 4 interventional study of Afrezza and insulin degludec in Diabetes Mellitus, Type 1, sponsored by Mannkind Corporation. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Mannkind Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 14th largest by enrollment, is the only one that started in 2023, is one of 4 in phase 4, and was the 34th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 1989; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 141 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 35 interventional studies. Of the 34 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 4, and was the 20th registered.
Mannkind Corporation’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 21 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to an insulin regimen of insulin degludec plus inhaled insulin (Afrezza) and CGM or continuation of usual care. The primary outcome of the RCT is at 17 weeks. The RCT will be followed by a 13-week extension phase in which participants in both groups will use the degludec-inhaled insulin regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Same treatment regimen (MDI, an AID system, or an insulin pump without automation) for the 3 months prior to screening
No medical, psychiatric,or other conditions, or medications being taken that in the Investigator's judgement would be a safety concern for participation in the study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase. Dexcom Continuous Glucose Monitoring (CGM) will be provided. The Afrezza-Degludec group will continue to use Afrezza and insulin degludec for an additional 13 weeks in the Extension Phase.
Biological: Afrezza · Biological: insulin degludec
The Usual Care group will continue to receive insulin as they did before the study. This could be by multiple daily injections (MDI) or by using an insulin pump with or without automation for the 17 weeks of the randomized controlled trial (RCT) Phase. Participants will continue to use their personal continuous glucose monitor (CGM) as they did before the study. The Usual Care group will then use Afrezza and insulin degludec for 13 weeks in the Extension Phase. Dexcom CGM will be provided during the Extension Phase.
Biological: Rapid-acting Insulin Analog · Biological: Basal Insulin
Pharmaceutical form: powder Route of administration: inhalation
Also known as: Technosphere Insulin
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Also known as: any FDA approved Rapid-acting Insulin Analog
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Also known as: any FDA approved Basal Insulin
Change in glycated hemoglobin (HbA1c)
Change in HbA1c from baseline to 17 weeks (non-inferiority margin 0.4%)
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured percent time with glucose less than 54 mg/dL
CGM-measured percent time with glucose \<54 mg/dL from baseline to 17 weeks (non-inferiority, margin 0.5%)
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured percent time with glucose less than 70 mg/dL
CGM-measured percent time with glucose \<70mg/dL from baseline to 17 weeks (non-inferiority, margin 2.0%)
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured daytime (0600-midnight) percent time in range with glucose 70-180 mg/dL
CGM-measured daytime (0600-midnight) percent time in range with glucose 70-180 mg/dL from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Mean Continuous Glucose Monitoring (CGM) glucose
Mean CGM glucose from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured (24-hours) percent time in range (TIR) with glucose 70-180 mg/dL
CGM-measured (24-hours) percent time in range with glucose 70-180 mg/dL from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured percent time with glucose greater than 180 mg/dL
CGM-measured percent time with glucose \> 180 mg/dL from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Change in glycated hemoglobin (HbA1c) for superiority assessment
HbA1c from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured time with glucose greater than 250 mg/dL
CGM-measured time with glucose \>250 mg/dL from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured time with glucose less than 70 mg/dL
CGM-measured time with glucose \<70 mg/dL from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured time with glucose less than 54 mg/dL
CGM-measured time with glucose \<54 mg/dL from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured coefficient of variation
CGM-measured coefficient of variation from baseline to 17 weeks, for superiority assessment
Time frame: 17 weeks
Change in HbA1c less than 7.0% at 17 weeks
HbA1c \<7.0% at 17 weeks
Time frame: 17 weeks
Change in HbA1c from baseline to 17 weeks, with an improvement of greater than 0.5%
HbA1c improvement from baseline to 17 weeks \>0.5%
Time frame: 17 weeks
Change in HbA1c from baseline to 17 weeks, with an improvement of greater than 1.0%
HbA1c improvement from baseline to 17 weeks \>1.0%
Time frame: 17 weeks
Percent time in range (TIR) with glucose 70-140 mg/dL
Percent time in range with glucose 70-140 mg/dL
Time frame: 17 weeks
Percent time with glucose greater than 300 mg/dL
Percent time with glucose \>300 mg/dL
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured prolonged hyperglycemia events
CGM-measured prolonged hyperglycemia events
Time frame: 17 weeks
Continuous Glucose Monitoring (CGM) measured hypoglycemia events
CGM-measured hypoglycemia events
Time frame: 17 weeks
Standard Deviation (SD) of glucose
SD of glucose
Time frame: 17 weeks
"Fasting glucose" by Continuous Glucose Monitoring (CGM)
"Fasting glucose" by CGM (defined as closest value to 6 a.m.; assumed, but not verified, with no food during the prior 4-hour period)
Time frame: 17 weeks
Percent time in range (TIR) with glucose 70-180 mg/dL greater than 70%
Percent time in range with glucose 70-180 mg/dL \>70% at 17 weeks
Time frame: 17 weeks
Percent time in range (TIR) with glucose 70-180 mg/dL improvement from baseline to 17 weeks greater than or equal to 5%
Percent time in range with glucose 70-180 mg/dL improvement from baseline to 17 weeks ≥5%
Time frame: 17 weeks
Percent time in range (TIR) with glucose 70-180 mg/dL improvement from baseline to 17 weeks ≥10%
Percent time in range with glucose 70-180 mg/dL improvement from baseline to 17 weeks ≥10%
Time frame: 17 weeks
Percent time with glucose less than 70 mg/dL less than 4%
Percent time with glucose \<70 mg/dL \<4% at 17 weeks
Time frame: 17 weeks
Percent time with glucose less than 54 mg/dL less than1%
Percent time with glucose \<54 mg/dL \<1% at 17 weeks
Time frame: 17 weeks
Percent time in range (TIR) 70-180 mg/dL greater than 70% and time less than 54 mg/dL less than 1%
Percent time in range 70-180 mg/dL \>70% and time \<54 mg/dL \<1% at 17 weeks
Time frame: 17 weeks
Incidence of severe hypoglycemia events
Incidence of severe hypoclycemia events, defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions
Time frame: 30 weeks
Continuous Glucose Monitoring (CGM) measured percent time with glucose less than 54 mg/dL
CGM-measured percent time with glucose less than 54 mg/dL
Time frame: 30 weeks
Other serious adverse events, including hospitalizations
Other serious adverse events, including hospitalizations
Time frame: 30 weeks
Incidence and severity of treatment-emergent adverse events (TEAEs)
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time frame: 30 weeks
Incidence and severity of adverse events of special interest (AESIs) as well as the number of participants with AESIs and number of individual events
Incidence and severity of adverse events of special interest (AESIs) as well as the number of participants with AESIs and number of individual events
Time frame: 30 weeks
Change from baseline to 17 weeks in Forced Expiratory Volume in one second (FEV1)
Change from baseline to 17 weeks in FEV1
Time frame: 17 weeks
Proportion of participants with Forced Expiratory Volume in one second (FEV1) reduction greater than or equal to 20%
Proportions of participants in each group who have experienced ≥20% reduction in FEV1 from baseline to Week 17
Time frame: 30 weeks
Hypoglycemic events from logged blood glucose measurements (BGM): Level 1 events (less than 70 mg/dL) and Level 2 events (less than 54 mg/dL) separately
Hypoglycemic events from logged BGM measurements: Level 1 events (\<70 mg/dL) and Level 2 events (\<54 mg/dL)
Time frame: 30 weeks
Hyperglycemic events from logged blood glucose measurements (BGM)
Hyperglycemic events from logged BGM measurements
Time frame: 30 weeks
Continuous Glucose Monitoring (CGM) measured prolonged hyperglycemia events
CGM-measured prolonged hyperglycemia events
Time frame: 30 weeks
Continuous Glucose Monitoring (CGM) measured hypoglycemia events (both a safety and efficacy endpoint)
CGM-measured hypoglycemia events (both a safety and efficacy endpoint)
Time frame: 30 weeks
Weight
Weight
Time frame: 17 weeks
Post prandial glucose for first meal challenge
Post prandial glucose for first meal challenge
Time frame: 17 weeks
Area under the curve (AUC) for first meal challenge
Area under the curve (AUC) for first meal challenge
Time frame: 17 weeks
Patient-reported outcome (PRO) questionnaires
Type 1 Diabetes Distress Scale (T1-DDS): 28-item validated survey pertaining to distress symptoms related to diabetes (recorded from a scale of 1 to 6). Hypoglycemia Confidence Scale (HCS): 9-item validated survey pertaining to situations where hypoglycemia could occur and queries about the participant's level of confidence in those situations (recorded from a scale 1 to 4). Insulin Treatment Satisfaction Questionnaire (ITSQ): 22-item survey with a 5-factor structure assessing insulin satisfaction (scores range from 0 to 100). Freedom and Flexibility: 6-item non-validated survey pertaining to life experiences impacted by having diabetes (scores range from 6 to 36) Insulin Adherence: 1-item non-validated survey pertaining to number of missed boluses in the past week
Time frame: 17 weeks
Change in HbA1c from baseline to 17 weeks, with a worsening of greater than 0.5%
Additional binary HbA1c endpoints, HbA1c worsening from baseline to 17 weeks \>0.5%
Time frame: 17 weeks
Change in HbA1c from baseline to 17 weeks, with a worsening of greater than 1.0%
Additional binary HbA1c endpoints, HbA1c worsening from baseline to 17 weeks \>1.0%
Time frame: 17 weeks
Percent time in range (TIR) with glucose 70-180 mg/dL worsening from baseline to 17 weeks greater than or equal to 5%
Additional binary CGM endpoints, Percent time in range with glucose 70-180 mg/dL worsening from baseline to 17 weeks ≥5%
Time frame: 17 weeks
Percent time in range (TIR) with glucose 70-180 mg/dL worsening from baseline to 17 weeks greater than or equal to 10%
Additional binary CGM endpoints, Percent time in range with glucose 70-180 mg/dL worsening from baseline to 17 weeks ≥10%
Time frame: 17 weeks
Ran from Jul 2023 to primary completion in Mar 2024, 8 months.
Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin, Regular, Human · Insulin degludec